论文部分内容阅读
11名健康有排卵女性,在预计排卵期前后口服事后片ovral 1片(内含炔雌醇0.1毫克+d1-18甲基炔诺酮1.0毫克),12小时后重复1次。在对照及用药周期从周期第八天起到月经来潮第一天止,每天用特异的放射免疫法测定血清黄体生成素(LH)、催乳激素(PRL)、孕酮(P)、17α-羟孕酮及雌二醇(E_2)水平,结果表明Ovral对血浆激素水平及周期长短的影响有明显的个体差异。9例于LH高峰时或其前服药,其中3例用药前后个体配对t试验表明,用药后LH峰显著降低(P<0.001),平均黄体期缩短为2天(对照周期平均为11天),此3例中2例在排卵前E_2峰之后用药,对照及用药周期的E_2水平相似,另1例于LH峰前3天用
Eleven healthy ovulated women were given oral ovral 1 tablet (ethinyl estradiol 0.1 mg + d1-18 norethisterone 1.0 mg) before and after the expected ovulation period and were repeated 12 hours later. In the control and medication cycles from the eighth day of the cycle to the first day of menstrual cramps, the levels of serum LH, PRL, P, 17α-OH were measured daily by specific radioimmunoassay Progesterone and estradiol (E 2) levels, the results showed that Ovral on plasma hormone levels and the length of the cycle there are significant individual differences. Nine patients took medication before or at the peak of LH. Paired t test of three patients before and after treatment showed that LH peak decreased significantly (P <0.001) and average luteal phase shortened to 2 days (average 11 days) Two of these three patients were administered E 2 before ovulation, the levels of E 2 in the control and medication cycles were similar, and the other one was used three days before LH peak